Professional Documents
Culture Documents
ESH-OnAir Programma Web96media
ESH-OnAir Programma Web96media
ESH-OnAir Programma Web96media
SCIENTIFIC PROGRAMME
SUNDAY, APRIL 11 SCIENTIFIC PROGRAMME
12.35-12.45 Q&A
3
SUNDAY, APRIL 11 SCIENTIFIC PROGRAMME
12.18-12.31 Precise vascular phenotype of blood pressure per se The 2018 ESC/ESH and 2020 ISH core-treatment
P. Boutouyrie (Paris, FRANCE) strategy: importance of SPCs*
A. Schutte (Sydney, AUSTRALIA)
12.31-12.36 Comments
J.-W. Ha (Seoul, SOUTH KOREA) 12.05-12.15 CASE 1: Always and which type of RAS-blocker as
backbone of therapy?
12.36-12.49 Digital transformation and artificial intelligence for P. van de Borne (Brussels, BELGIUM)
precise hypertension
K. Kario (Tochigi, JAPAN) 12.15-12.25 CASE 2: Which patient should be still started with
monotherapy?
12.49-12.54 Comments J. Brguljan (Ljubljana, SLOVENIA)
T. Weber (Wels, AUSTRIA)
12.25-12.35 CASE 3: Which patient should be referred to a
12.54-13.00 Discussion specialist?
A. Januszewicz (Warsaw, POLAND)
4
SUNDAY, APRIL 11 SCIENTIFIC PROGRAMME
12.00-13.00 - ROOM 3
12.35-12.45 Strategies to prevent salt-induced hypertension
19 International SHR Symposium
th T. Kurtz (San Francisco, CA, USA)
5
SUNDAY, APRIL 11 SCIENTIFIC PROGRAMME
12.00-14.00 - ROOM 4
BIHS Symposium
SESSION 1: SESSION 2:
OLD AND NEW CHALLENGES IN PRIMARY CARE REMOTE CONSULTATIONS AND VIRTUAL CLINICS
Chairpersons: U. Martin (Birmingham, UNITED KINGDOM),
J. Moore (London, UNITED KINGDOM)
13.00-13.05 Introduction
U. Martin (Birmingham, UNITED KINGDOM),
J. Moore (London, UNITED KINGDOM)
12.00-12.05 Introduction
U. Martin (Birmingham, UNITED KINGDOM),
13.05-13.25 Remote consultations and virtual clinics: experience
J. Moore (London, UNITED KINGDOM)
from COVID-19
M. Glover (Nottingham, UNITED KINGDOM)
12.05-12.25 Measuring BP in primary care: practical aspects and
the role of AHPs
13.25-13.35 Home blood pressure measurement: opportunities and
S. McDonagh (Exeter, UNITED KINGDOM)
challenges
T. McCormack (London, UNITED KINGDOM)
12.25-12.35 Adherence and treatment resistance
I. Mackenzie (Dundee, UNITED KINGDOM)
13.35-13.45 Advances in telemonitoring
R. McManus (Oxford, UNITED KINGDOM)
12.35-12.45 Hypertensive emergencies: same day referral to
secondary care
13.45-14.00 Panel discussion and Q&A
M. Okorie (Brighton, UNITED KINGDOM)
6
SUNDAY, APRIL 11 SCIENTIFIC PROGRAMME
7
SUNDAY, APRIL 11 SCIENTIFIC PROGRAMME
13.05-13.25 Triple single-pill combination: what do the guidelines 13.05-13.20 How to improve previous guidelines?
tell us? A. Avolio (Sydney, AUSTRALIA)
K. Narkiewicz (Gdansk, POLAND)
13.20-13.35 The experience with BP measuring devices
13.25-13.45 Pros and cons of RAAS inhibitors and diuretics J. Sharman (Hobart, AUSTRALIA)
A.A. Brandão (Rio de Janeiro, BRAZIL)
13.35-13.50 Where do we stand?
13.45-14.00 Discussion and conclusion R.M. Bruno (Paris, FRANCE)
13.50-14.00 Discussion
8
SUNDAY, APRIL 11 SCIENTIFIC PROGRAMME
13.50-14.00 Discussion
9
SUNDAY, APRIL 11 SCIENTIFIC PROGRAMME
10
SUNDAY, APRIL 11 SCIENTIFIC PROGRAMME
14.00-14.05 Session discussion and live introduction 14.00-14.25 Hypertension and cerebrovascular disease
K. Tsioufis (Athens, GREECE) S. Stabouli (Thessaloniki, GREECE)
14.05-14.15 The evidence for radiofrequency ablation as a 14.25-14.50 HyperChildNET: Towards the future of hypertension in
hypertension treatment option children and adolescents
A. Sharp (Cardiff, UNITED KINGDOM) E. Lurbe (Valencia, SPAIN)
11
SUNDAY, APRIL 11 SCIENTIFIC PROGRAMME
ESH Working Group on Hypertension and ESH Working Group on Endothelins and
the Kidney Endothelial Factors
ADVANCES ON DIAGNOSIS, PATHOPHYSIOLOGY UNSOLVED ISSUES IN ENDOTHELIAL DYSFUNCTION
AND TREATMENT OF HYPERTENSION IN IN ARTERIAL HYPERTENSION
PATIENTS WITH CKD Chairpersons: G.P. Rossi (Padua, ITALY) ,
Chairpersons: J.-M. Halimi (Tours, FRANCE), T.M. Seccia (Padua, ITALY)
P. Sarafidis (Thessaloniki, GREECE)
14.50-15.00 Discussion
12
SUNDAY, APRIL 11 SCIENTIFIC PROGRAMME
14.00-15.00 - ROOM 4
CASE 1
14.12-14.22 Patient on diuretics
D. Terentes-Printzios (Athens, GREECE)
14.22-14.24 Discussion
M. Doumas (Thessaloniki, GREECE)
CASE 2
14.24-14.34 Patient on beta-blockers
K. Imprialos (Thessaloniki, GREECE)
14.34-14.36 Discussion
V. Stojanov (Belgrade, SERBIA)
13
SUNDAY, APRIL 11 SCIENTIFIC PROGRAMME
14.50-15.00 Discussion
14
SUNDAY, APRIL 11 SCIENTIFIC PROGRAMME
Minisymposium Minisymposium
supported by Bayer supported by Menarini Group
PROTECTING THE BRAIN: WHY KIDNEYS MATTER? LESSON FROM THE COURTROOM
Chairperson: R. Kreutz (Berlin, GERMANY) Chairpersons: G. Ambrosio (Perugia, ITALY),
C. Borghi (Bologna, ITALY)
15
SUNDAY, APRIL 11 SCIENTIFIC PROGRAMME
15.20-15.30 Results of the Hevro study 15.07 VALIDITY OF FIVE FORMULAS TO ESTIMATE 24-HOUR
P. Iliakis (Athens, GREECE) URINARY SODIUM BY SPOT URINE SAMPLES IN ADULTS LIVING IN
NORTHEAST CHINA
15.30-15.40 Chronic kidney disease and aging - results from EHUH W. Song, N. Qian, R. Guo, Y. Zhang, Y. Jiang
and ENAH studies Dalian, CHINA
M. Matasin (Zagreb, CROATIA)
15.14 SYSTOLIC INTER-ARM BLOOD PRESSURE DIFFERENCE
15.40-15.50 Resistant hypertension - experience from two centers AND COGNITIVE DECLINE: FINDINGS FROM THE INTERPRESS-IPD
N. Radivojecic (Belgrade, SERBIA), A. Jelakovic (Zagreb, COLLABORATION
CROATIA) C. Clark 1, K. Boddy 1, F. Warren 1, S. Mcdonagh 1, S. Moore 1, V. Aboyans
2
, L. Cloutier 3, R. Mcmanus 4, A. Shore 1, R. Taylor 1,5, J. Campbell 1
15.50-16.00 How to establish national registry on fibromuscular 1
Exeter, UNITED KINGDOM, 2 Limoges, FRANCE, 3 Québec, CANADA,
dysplasia and join European/International registry 4
Oxford, 5 Glasgow, UNITED KINGDOM
Ž. Dika (Zagreb, CROATIA), M. Stojanovic (Belgrade,
SERBIA), M. Dorobantu (Bucharest, ROMANIA), 15.21 SYSTOLIC BLOOD PRESSURE IS A MAJOR COMPONENT
A. Triantafyllou (Thessaloniki, GREECE) OF THE RISK SCORE FOR NEW PROGRESSION OF CAROTID
PLAQUE: THE SUITA STUDY
Y. Kokubo, M. Watanabe, A. Higashiyama, K. Honda-Kohmo, Y. Miyamoto
Suita, JAPAN
16
SUNDAY, APRIL 11 SCIENTIFIC PROGRAMME
15.00-16.00 - ROOM 5
15.28 ORTHOSTATIC BLOOD PRESSURE CHANGES
AND SUBCLINICAL MARKERS OF ATHEROSCLEROSIS IN ESH Working Group on Endocrine
NORMOTENSIVE ADULTS. RESULTS FROM A NATIONAL-
REPRESENTATIVE SURVEY Hypertension
O.F.G. Gheorghe Fronea 1, R. Darabont 1, C. Pop 2, M. Dorobantu 1 Chairpersons: P. Mulatero (Turin, ITALY),
1
Bucharest, 2 Baia Mare, ROMANIA J. Widimský jr. (Prague, CZECH REPUBLIC)
17
SUNDAY, APRIL 11 SCIENTIFIC PROGRAMME
15.00-16.00 - ROOM 6
15.28 GENES ASSOCIATED WITH BLOOD PRESSURE TRAITS
Oral Session 1B SHOW CELL TYPE-SPECIFIC EXPRESSION AND CONTROL
MULTIPLE CAUSAL LINKS TO BLOOD PRESSURE
REGULATION IN THE HUMAN KIDNEY
GENETICS, GENOMICS, PROTEOMICS,
J. Eales 1, X. Jiang 1, X. Xu 1, S. Saluja 1, E. Cano-Gamez 2, S. Pramanik 1,
METABOLOMICS P. Bogdanski 3, W. Wystrychowski 4, J. Zywiec 5,
Chairpersons: F.J. Charchar (Ballarat, AUSTRALIA), E. Zukowska-Szczechowska 4, A. Woolf 1, P. Maffia 6, T. Guzik 6,
G. Ehret (Geneva, SWITZERLAND) N. Samani 7, F. Charchar 8, M. Tomaszewski 1
1
Manchester, 2 Cambridge, UNITED KINGDOM, 3 Poznan, 4 Katowice,
5
Zabrze, POLAND, 6 Glasgow, 7 Leicester, UNITED KINGDOM,
15.00 KIDNEY DNA METHYLATION AS A DRIVER OF HERITABLE 8
Ballarat, AUSTRALIA
PREDISPOSITION TO BLOOD PRESSURE AND HYPERTENSION
X. Xu 1, J. Eales 1, X. Jiang 1, H. Guo 1, N. Samani 2, F. Charchar 3, 15.35 LEFT VENTRICULAR MASS AND URINARY METABOLOMICS
M. Tomaszewski 1 IN YOUNG BLACK AND WHITE ADULTS: THE AFRICAN-PREDICT
1
Manchester, 2 Leicester, UNITED KINGDOM, 3 Victoria, AUSTRALIA STUDY
D. de Beer 1, C. McMels 1, A.E. Schutte 1, R. Louw 1, C. Delles 2,
15.07 CIRCULATING METABOLIC BIOMARKERS AS POTENTIAL R. Kruger 1
LEADS FOR GLOBAL PREVENTION OF RENAL DYSFUNCTION – A 1
Potchefstroom, SOUTH AFRICA, 2 Glasgow, UNITED KINGDOM
FLEMISH COHORT STUDY
Z.-Y. Zhang 1, V. Marrachelli 2, W.-Yi Yang 1, L. Thijs 1, D. Monleon 2, 15.42 LECTURE
P. Verhamme 1, J. Redón 2, J. Staessen 1 GENOMICS OF BLOOD PRESSURE IN TWENTIES
1
Leuven, BELGIUM, 2 Valencia, SPAIN M.J. Caulfield (London, UNITED KINGDOM)
18
SUNDAY, APRIL 11 SCIENTIFIC PROGRAMME
Minisymposium Minisymposium
supported by Menarini Group supported by an unrestricted educational grant from AstraZeneca
16.40-16.45 Q&A
19
SUNDAY, APRIL 11 SCIENTIFIC PROGRAMME
16.30-16.40 RADIANCE-HTN TRIO: a review of study design and its 16.14 PROXIMAL TUBULE-SPECIFIC DELETION OF AT1A
significance RECEPTORS ATTENUATES CIRCULATING AND INTRATUBULAR
M. Azizi (Paris, FRANCE) ANGIOTENSIN II-INDUCED HYPERTENSION IN MICE
X. Li 1, A.P. Leite 1, X. Zheng 2, C. Zhao 2, L. Zhang 1, X. Chen 3, X. Zhou 3,
J. Zhuo 1
16.40-16.45 Session evaluation and key learnings 1
New Orleans, LA, USA, 2 Nanning, CHINA, 3 Jackson, MS, USA
R.E. Schmieder (Erlangen, GERMANY)
16.21 LONG TERM BENEFITS OF BLOOD PRESSURE TREATMENT
ON THE INCIDENCE OF ATRIAL FIBRILLATION, HEART FAILURE
AND CARDIOVASCULAR MORBIDITY AND MORTALITY: 20-YEARS
FOLLOW-UP OF ASCOT-LEGACY
A. Gupta 1, W. Whiteley 2, T. Godec 1, S. Rostamian 1, A. Whitehouse 1,
J. Mackay 1, P. Sever 1
1
London, 2 Edinburgh, UNITED KINGDOM
20
SUNDAY, APRIL 11 SCIENTIFIC PROGRAMME
16.00-17.00 - ROOM 5
16.28 SAFETY, PHARMACODYNAMICS, AND BLOOD PRESSURE
EFFECTS OF ALN-AGT, AN RNA INTERFERENCE THERAPEUTIC
TARGETING ANGIOTENSINOGEN, IN A RANDOMIZED SINGLE
Oral Session 2A
ASCENDING DOSE STUDY OF HYPERTENSIVE ADULTS
S. A. Huang 1, J. Taubel 2, G. Fiore 3, P. Dewland 3, D.J. Webb 4, RESISTANT HYPERTENSION - INTERVENTIONAL
G.L. Bakris 5, A.S. Desai 6, Y. Cheng 1, S. Agarwal 1, J. Harrop 1, THERAPIES
H.V. Nguyen 1, J. Lu 1, D. Foster 1, K. Fujita 1
1
Cambridge, MA, USA, 2 London, 3 Manchester, 4 Edinburgh, UNITED Chairpersons: A. Prejbisz (Warsaw, POLAND),
KINGDOM, 5 Chicago, IL, 6 Boston, MA, USA M. Schlaich (Perth, AUSTRALIA)
21
SUNDAY, APRIL 11 SCIENTIFIC PROGRAMME
16.00-17.00 - ROOM 6
16.36 CARDIOVASCULAR OUTCOMES AND ALL-CAUSE
MORTALITY ASSOCIATED WITH APPARENT TREATMENT- Oral Session 2B
RESISTANT HYPERTENSION APPLYING THE 2017 ACC/AHA
GUIDELINE
EPIDEMIOLOGY OF HYPERTENSION AND
A. Jaejin 1, J. Sim 2, R. Lui 1, H. Zhou 1, D. Calhoun 3, R. Wei 1, T. Luong 1,
K. Reynolds 1 METABOLIC DISORDERS
1
Pasadena, CA, 2 Los Angeles, CA, 3 Birmingham, AL, USA Chairpersons: N. Khan (Vancouver, CANADA),
D. Lovic (Niš, SERBIA)
16.43 ESTABLISHING SERUM REFERENCE RANGES OF
ANTIHYPERTENSIVE DRUGS
S. Rognstad 1 C. Lund Søraas 1, O. Undrum Bergland 1, A. Høieggen 1,2, 16.00 SELF-TESTING OF BLOOD PRESSURE ACCORDING TO THE
M. Strømmen 2, A. Helland 2, M. Stokke Opdal 1 DEPISTHTA® PROTOCOL IN THE POPULATION OF THE FRENCH
1
Oslo, 2 Trondheim, NORWAY LEAGUE AGAINST HYPERTENSION SURVEY 2019
X. Girerd, A. Pathak, B. Vaïsse, O. Hanon
16.50 PATIROMER VS PLACEBO TO ENABLE SPIRONOLACTONE Paris, FRANCE
IN PATIENTS WITH RESISTANT HYPERTENSION AND CKD:
ANALYSIS ACCORDING TO PATIENT SEX (AMBER TRIAL) 16.07 LACK OF FUNDING AND LONG-TERM JOB
B. Williams 1, W.B. White 2, M.R. Mayo 3, S. Warren 3, S. Arthur 3, SECURITY THREATENS TO HAVE PROFOUND EFFECTS ON
G. Ackourey 3, P. Rossignol 4, R. Agarwal 5 CARDIOVASCULAR RESEARCHER RETENTION IN AUSTRALIA
1
London, UNITED KINGDOM, 2 Farmington, CT, 3 Redwood City, CA, USA, F. Marques 1, R. Climie 1, J. Wu 2, A. Calkin 1, N. Chapman 3, K. Colafella 1,
4
Nancy, FRANCE, 5 Indianapolis, IN, USA D. Picone 3, H. Viola 4, A. Murphy 1, M. Nelson 3, S. Nichols 1, L. Hool 4,
G. Figtree 2
1
Melbourne, 2 Sydney, 3 Hobart, 4 Perth, AUSTRALIA
22
SUNDAY, APRIL 11 SCIENTIFIC PROGRAMME
23
MONDAY, APRIL 12 SCIENTIFIC PROGRAMME
11.00-11.12 Associations between pregnancy hypertensive 11.00-11.25 Relationship between hypertension and associated
disorders and common cardiovascular disorders: cardiovascular risk factors on cardiovascular prognosis
the CALIBER study in Spain
L. Chappell (Oxford, UNITED KINGDOM) J. Polo Garcia (Caceres, SPAIN)
11.12-11.24 Cardiovascular risk in women after preeclampsia/ 11.25-11.50 Cardiovascular risk and kidney disease in patients seen
hypertension in pregnancy: a link to microvascular by Primary Care physicians in Spain
dysfunction? R. Mico’ Pérez (Valencia, SPAIN)
R. Dechend (Berlin, GERMANY)
11.50-12.00 Conclusion and discussion
11.24-11.36 Peri-partum management of hypertension A. Coca (Barcelona, SPAIN)
R. Cifková (Prague, CZECH REPUBLIC)
11.48-12.00 Discussion
26
MONDAY, APRIL 12 SCIENTIFIC PROGRAMME
11.00-12.00 - ROOM 2
SECTION 1 SECTION 2
Chairpersons: E. Ogola (Nairobi, KENYA), Chairpersons: Y. Kokubo (Suita, Osaka, JAPAN),
A. Schutte (Sydney, AUSTRALIA), A. Ramirez (Buenos Aires, ARGENTINA),
M.A. Weber (Brooklyn, NY, USA) R. Wainford (Boston, MA, USA)
11.08-11.13 Definition of hypertension and blood pressure 11.43-11.48 Pregnancy, emergencies and other issues
measurement N. Khan (Vancouver, CANADA)
G.S. Stergiou (Athens, GREECE)
11.48-11.53 Ethnic aspects
11.13-11.18 Diagnostics and HMOD D. Prabhakaran (Gurugram, INDIA)
M. Schlaich (Perth, AUSTRALIA)
11.53-11.58 Hypertension Guidelines at a glance
11.18-11.23 Lifestyle modifications T. Unger (Maastricht, THE NETHERLANDS)
F.J. Charchar (Ballarat, AUSTRALIA)
11.58-12.00 Discussion
11.23-11.28 Optimal treatment standards
B. Williams (London, UNITED KINGDOM)
27
MONDAY, APRIL 12 SCIENTIFIC PROGRAMME
28
MONDAY, APRIL 12 SCIENTIFIC PROGRAMME
11.00-12.00 - ROOM 5
11.28 CYB5R3 BIASES SOLUBLE GUANYLYL CYCLASE
ACTIVATION IN RESISTANCE ARTERIES Oral Session 3B
B. Durgin, S. Hahn, A. Straub
Pittsburgh, PA, USA
MICROCIRCULATION AND SMALL VESSELS
11.35 HYPOTENSIVE EFFECTIVENESS OF THE INTRARENAL Chairpersons: M. Dorobantu (Bucharest, ROMANIA),
MEDULLARY ENDOTHELIN ETA RECEPTOR BLOCKADE IN THE R.M. Touyz (Glasgow, UNITED KINGDOM)
TWO ANIMAL MODELS OF HYPERTENSION
B. Badzynska 1, J. Sadowski 1, I. Vaneckova 2,
E. Kompanowska-Jezierska 1 11.00 INFLUENCE OF RENAL FUNCTION ON RETINAL VASCULAR
1
Warsaw, POLAND, 2 Prague, CZECH REPUBLIC DENSITY ASSESSED BY OCT ANGIOGRAPHY IN HYPERTENSIVE
PATIENTS
11.42 NOX4 PROTECTIVE EFFECT IN ENDOTHELIAL FUNCTION G. Mulè, M. Vadalà, G. Guarrasi, L. Guarino, M. Castellucci, A. Sorce,
INVOLVES ACTIVATION OF TRANSIENT RECEPTOR POTENTIAL R. Dell’Utri, A. Ferotti, S. Cillino, S. Cottone
MELASTATIN 2 (TRPM2) CATION CHANNEL Palermo, ITALY
R. Alves-Lopes, K. Neves, A. Montezano, R. Touyz
Glasgow, UNITED KINGDOM 11.07 NOX5 AND VASCULAR SIGNALLING IN HUMAN
HYPERTENSION
11.49 INTROGRESSION OF A BROWN NORWAY CHROMOSOME 2 L. Camargo 1, A. Montezano 1, M. Hussain 2, Y. Wang 1, Z. Zou 1, F. Rios 1,
FRAGMENT INTO DAHL SALT-SENSITIVE RATS EXERTS ANTI- AND F. Awan 2, R. Touyz 1
PRO-INFLAMMATORY EFFECTS UNDER A NORMAL AND HIGH- 1
Glasgow, UNITED KINGDOM, 2 Faisalabad, PAKISTAN
SALT DIET, RESPECTIVELY
O. Berillo 1, S. Ouerd 1, A. Rehman 1, C. Richer 1, D. Sinnett 1, A.E. Kwitek 2, 11.14 ROLE OF INHIBITION OF CGMP-DEPENDENT PROTEIN
P. Paradis 1, E.L. Schiffrin 1 KINASE (PKG) SIGNALLING ON ANTICONTRACTILE FUNCTION OF
1
Montreal, CANADA, 2 Milwaukee, WI, USA PERIVASCULAR ADIPOSE TISSUE
C. Agabiti Rosei, C. Rossini, C. De Ciuceis, E. Porteri, V. Brami, M. Nardin,
G. Chiarini, A. Petelca, M.A. Coschignano, G. A. Tiberio, M.L. Muiesan,
D. Rizzoni
Brescia, ITALY
29
MONDAY, APRIL 12 SCIENTIFIC PROGRAMME
11.00-12.00 - ROOM 6
11.28 STRUCTURAL ALTERATIONS OF MICROCIRCULATION IN
CANCER PATIENTS TREATED WITH ANTIANGIOGENIC DRUGS Workshop
V. Brami, M. A. Coschignano, C. De Ciuceis, C. Rossini, A. Berruti,
C. Agabiti Rosei, A. Paini, D. Cosentini, A. Dalla Volta, M. Salvetti,
HYPERTROPHY OF THE HEART - THE KEY/CENTRAL
E. Porteri, A. Petelca, M. Nardi, G. Chiarini, M.L. Muiesan, D. Rizzoni
Brescia, ITALY HMOD REVISITED
Chairpersons: T. de Backer (Ghent, BELGIUM),
11.35 RELATIONSHIPS BETWEEN CHOROIDAL THICKNESS AND A.M. Heagerty (Manchester, UNITED KINGDOM)
24H PULSE PRESSURE IN HYPERTENSIVE PATIENTS
G. Mulè, M. Vadala, G. Guarrasi, A. Sorce, K. Montalbano, C. Carollo,
E. Mancia, S. Cottone 11.00-11.20 Left ventricular hypertrophy (LVH) is a key prognostic
Palermo, ITALY indicator in hypertension. Diagnosis and mechanisms
E. Agabiti Rosei (Brescia, ITALY)
11.42 LECTURE
THE ANGIOTENSIN AT2-RECEPTOR: NEW INSIGHTS INTO ITS 11.20-11.40 The role of LVH as the key Hypertension Mediated
NATURE AND INTO CLINICAL DEVELOPMENT Organ Damage (HMOD) in the European Hypertension
U.M. Steckelings (Odense, DENMARK) Guidelines revisited. Regression of LVH during
treatment and less cardiovascular complications
S.E. Kjeldsen (Oslo, NORWAY)
30
MONDAY, APRIL 12 SCIENTIFIC PROGRAMME
31
MONDAY, APRIL 12 SCIENTIFIC PROGRAMME
32
MONDAY, APRIL 12 SCIENTIFIC PROGRAMME
13.00-14.00 - ROOM 3
13.36 POPULATION ATTRIBUTABLE FRACTION OF
HYPERTENSION FOR ONSET OF ISCHEMIC STROKE AMONG Oral Session 4B
ATRIAL FIBRILLATION PATIENTS WITH AND WITHOUT
ANTICOAGULATION
DIABETES
T. Maeda, T. Nishi, S. Funakoshi, K. Tada, M. Tsuji, A. Satoh, M. Kawazoe,
C. Yoshimura, H. Arima Chairpersons: D. Burger (Ottawa, CANADA),
Fukuoka, JAPAN V. Kotsis (Thessaloniki, GREECE)
33
MONDAY, APRIL 12 SCIENTIFIC PROGRAMME
13.00-14.00 - ROOM 5
13.28 MODULATION OF SYMPATHETIC NERVE ACTIVITY BY
SGLT2 INHIBITOR EMPAGLIFLOZIN IN DIABETIC RABBITS Oral Session 4C
C. Gueguen 1, S.L. Burke 1, B. Barzel 1, K. Lim 1, N. Eikelis 1, A. Watson 1,
J.C. Jha 1, K.L. Jackson 1, Y. Sata 1, G.W. Lambert 1, K. Jandeleit-Dahm 1,2,
PREGNANCY
M.E. Cooper 1, M.C. Thomas 1, G.A. Head 1
1
Melbourne, AUSTRALIA, 2 Düsseldorf, GERMANY Chairpersons: R. Cifková (Prague, CZECH REPUBLIC),
T. Unger (Maastricht, THE NETHERLANDS)
13.35 PREDIABETES, PREHYPERTENSION AND RISK FOR
ALL-CAUSE AND CARDIOVASCULAR MORTALITY AMONG US
ADULTS: RESULTS FROM THE NATIONAL HEALTH AND NUTRITION 13.00 SODIUM ACETATE AND EPLERENONE RESTORE RENAL
EXAMINATION SURVEYS GLUTATHIONE AND ADENOSINE CONTENT OF RATS EXPOSED TO
C.-L. Chen 1, L. Liu 1, J.-Y. Huang 1, Y.-L. Yu 1, G. Shen 1, K. Lo 2, TESTOSTERONE DURING LATE GESTATION
Y.-Q. Huang 1, Y.-Q. Feng 1 T. Usman 1, O. Adeyanju 2, E. Areola 3, O. Badmus 4, K. Olaniyi 2,
1
Guangzhou, CHINA, 2 Providence, RI, USA I. Oyeyipo 1, L. Olatunji 3
1
Osogbo, 2 Ado-Ekiti, 3 Malete, 4 Ilorin, NIGERIA
13.42 THE EFFECT OF DAPAGLIFLOZIN ON 24-HOUR BLOOD
PRESSURE AND ARTERIAL STIFFNESS IN PATIENTS WITH TYPE-2 13.07 PREVALENCE OF CHRONIC HYPERTENSION IN PREGNANT
DIABETES MELLITUS: A DOUBLE-BLIND RANDOMIZED CLINICAL WOMEN FOLLOWING THE 2017 ACC/AHA GUIDELINE CHANGE IN
TRIAL DIAGNOSTIC CRITERIA FOR HYPERTENSION
E. Papadopoulou, C. Loutradis, G. Tzatzagou, K. Kotsa, I. Zografou, K. Reynolds 1, H. Zhou 1, Z. Bider-Canfield 1, T.C. Cheetham 2, C. Portugal 1,
I. Minopoulou, M. Theodorakopoulou, A. Tsapas, A. Karagiannis, N.A. Bello 3
P. Sarafidis 1
Pasadena, CA, 2 Irvine,CA, 3 New York, NY, USA
Thessaloniki, GREECE
13.14 NOVEL MIRNAS AS TARGETS OF MESENCHYMAL STEM
13.49 SATURATED FATTY ACIDS IN ERYTHROCYTE MEMBRANES CELLS-BASED THERAPY FOR TREATMENT OF PREECLAMPSIA
IN ADOLESCENTS WITH TYPE 1 DIABETES MELLITUS A. Alqudah 1, S. Suvakov 2, C. Richards 3, N. Todd 1, K.-A. Eastwood 1,
D. Marcon, A. Tagetti, A. Giontella, G. Monamì, L. Branz, S. Bortolotti, A.J. Hunter 1, V.A. Holmes 1, D.R. McCance 1, I.S. Young 1, F. Furlong 1,
C. Piona, A. Morandi, L. Trento, P. Minuz, C. Maffeis, C. Fava A. Ali 1, A. Krasnodembskaya 1, G. Lopez-Campos 1, V.D. Garovic 2,
Verona, ITALY L. McClements 1,3
1
Belfast, UNITED KINGDOM, 2 Rochester, USA, 3 Sydney, AUSTRALIA
34
MONDAY, APRIL 12 SCIENTIFIC PROGRAMME
13.00-14.00 - ROOM 6
13.28 ATTENUATION OF PLACENTAL LIPID DEPOSITION BY
GLUTAMINE SUPPLEMENTATION IMPROVES FETAL OUTCOME IN ISH Regional Advisory Group - South and
INSULIN-RESISTANT PREGNANT RATS
K. Olaniyi 1, L. Olatunji 2 Central Asia
1
Ado-Ekiti, 2 Ilorin, NIGERIA Chairpersons: M. Ishaq (Karachi, PAKISTAN),
M.-C. Cho (Cheongju, SOUTH KOREA)
13.35 THE IMPORTANCE OF B2 CELLS IN THE HYPERTENSION
AND PATHOPHYSIOLOGY OF PLACENTAL ISCHEMIA DURING
PREGNANCY 13.00-13.05 ISH (SACA) RAG introduction and objectives
B. Lamarca, O. Herrock, S. Fitzgerald, J. Lemon, E. Deer, T. Ibrahim, M. Ishaq (Karachi, PAKISTAN)
N. Campbell, L. Amaral
Jackson, MS, USA 13.05-13.20 High blood pressure and its determinants among rural
adults of Bangladesh: baseline findings of WHO PEN
13.42 LOW DOSE SPIRONOLACTONE PROTECTS implementation
EXPERIMENTALLY-INDUCED POLYCYSTIC OVARIAN SYNDROME L. Barua (Dhaka, BANGLADESH)
FROM INSULIN-RESISTANT METABOLIC DISTURBANCES
O. Adeyanju, T. Falodun 13.20-13.35 Education in hypertension in South and Central Asia:
Ado-Ekiti, NIGERIA opportunities and challenges
M. Patil (Pune, INDIA)
13.49 MODULATION OF ANGIOGENIC BALANCE DURING
PREGNANCY BY EXOGENOUS HEPARIN 13.35-13.50 Insights from the Pakistan hypertension league
K. Moore, H. Chapman, E. George M. Ishaq (Karachi, PAKISTAN)
Jackson, MS, USA
13.50-14.00 Discussion
35
MONDAY, APRIL 12 SCIENTIFIC PROGRAMME
Minisymposium Minisymposium
supported by Omron Healthcare supported by Vifor Pharma
HOME BLOOD PRESSURE-GUIDED MANAGEMENT ENABLING RAASI THERAPY THROUGH LONG TERM
OF HYPERTENSION POTASSIUM CONTROL IN PATIENTS WITH
Chairperson: B. Williams (London, UNITED KINGDOM) THE HIGHEST UNMET NEED
Chairperson: J. Cleland (Glasgow, UNITED KINGDOM)
36
MONDAY, APRIL 12 SCIENTIFIC PROGRAMME
37
MONDAY, APRIL 12 SCIENTIFIC PROGRAMME
14.39-14.48 Improving access through e-learning - e-CCMH 14.29 SODIUM INTAKE, LIFE EXPECTANCY AND ALL-CAUSE
initiative MORTALITY
M. Turner (Dallas, TX, USA) F. Messerli 1,2,3, L. Hoftetter 1, L. Syrogiannouli 1, E. Rexhaj 1, G. Siontis 1,
C. Seiler 1, S. Bangalore 3
14.48-15.00 Q&A session 1
Bern, SWITZERLAND, 2 Krakow, POLAND, 3 New York, NY, USA
38
MONDAY, APRIL 12 SCIENTIFIC PROGRAMME
14.00-15.00 - ROOM 6
14.43 THE ASSOCIATIONS BETWEEN HYPERTENSION AND
STROKE FROM MAY MEASUREMENT MONTH AND BETWEEN ISH Austin Doyle Award Session
NATIONAL HYPERTENSION PARAMETERS WITH STROKE
MORTALITY FROM THE GLOBAL BURDEN OF DISEASE Chairpersons: N. Jessen (Maputo, MOZAMBIQUE),
Q. Lin, T. Ye, T. Beaney, N. R. Poulter C. Mills (Reading, UNITED KINGDOM)
London, UNITED KINGDOM
14.00 STUDY ON REDUCTION OF MICROALBUMINURIA
14.50 FEASIBILITY AND ACCEPTABILITY OF A NOVEL AMONGST HYPERTENSIVE PATIENTS WITH USE OF TRIPLE
INTEGRATION OF ABSOLUTE CARDIOVASCULAR DISEASE RISK COMBINATION THERAPY (TRIPLIXAM)
ASSESSMENT INTO ROUTINE BLOOD CHOLESTEROL TESTING A. Arun
N. Chapman, R. Fonseca, L. Murfett, K. Beazley, R. McWhirter, Lucknow, INDIA
M. Schultz, M. Nelson, J. Sharman
14.12 CHARACTERIZATION OF GLUCOSE UPTAKE METABOLISM
Hobart, AUSTRALIA
IN VISCERAL FAT BY 18F-FDG PET/CT REFLECTS INFLAMMATORY
STATUS IN METABOLIC SYNDROME
K. Pahk, E. J. Kim, Y.-J. Lee, S. Kim, H. Seog Seo
Seoul, SOUTH KOREA
39
MONDAY, APRIL 12 SCIENTIFIC PROGRAMME
40
MONDAY, APRIL 12 SCIENTIFIC PROGRAMME
15.00-15.45 - ROOM 2
15.28 RENAL OXIDATIVE STRESS IN A MODEL OF
HYPERTENSION INDUCED BY SALINE OVERLOAD: ROLE OF Minisymposium
CHLORIDE ANION
supported by ReCor Medical
A.M. Puyó 1, N.M. Kouyoumdzian 2, P.D. Prince 2, G.D. Robbesaul 2,
G. Kim 2, M. Pandolfo 2, B.E. Fernández 2, M.L. Galleano 2, M.R. Choi 1,2
1
Buenos Aires, 2 Caba, ARGENTINA WHICH PATIENTS SHOULD BE CONSIDERED FOR
ULTRASOUND RDN AND HOW TO BUILD AN
15.35 TUBULOINTERSTITIAL INJURY WAS SUPPRESSED BY INTERVENTIONAL HYPERTENSION MANAGEMENT
INHIBITION OF PLATELET-DERIVED GROWTH FACTOR PATHWAY IN PRACTICE
RAT RENAL VENOUS CONGESTION MODEL
T. Hirose, T. Matsuki, C. Takahashi, I. Oba-Yabana, T. Kato, R. Tajima, Chairperson: G. Parati (Milan, ITALY)
T. Seki, S. Kinugasa, H. Nakamura, J. Tani, T. Mori
Sendai, JAPAN
15.00-15.05 Session objectives
15.42 RENAL FUNCTIONAL RESERVE IS RELATED TO THE G. Parati (Milan, ITALY)
NON-DIPPING PHENOTYPE AND TO THE EXERCISE HEART RATE
RESPONSE IN PATIENTS WITH ESSENTIAL HYPERTESION AND A 15.05-15.15 State of RDN today and recent clinical developments
PRESERVED RENAL FUNCTION M. Schlaich (Perth, AUSTRALIA)
K. Damianaki 1, M. Burnier 2, K. Tsioufis 1, K. Dimitriadis 1, D. Vlahakos 1,
D. Petras 1 15.15-15.30 What do referring physicians need to know: patient
1
Athens, GREECE, 2 Lausanne, SWITZERLAND screening, patient preference
J. Weil (Lubeck, GERMANY)
15.49 INITIAL EGFR DECLINE AND LONG-TERM RENAL
FUNCTION DURING BLOOD PRESSURE LOWERING THERAPY: A 15.30-15.40 Review of consensus statements and guidelines: what
PATIENT LEVEL META-ANALYSIS OF THE SPRINT AND ACCORD-BP is needed next?
RANDOMIZED CONTROLLED TRIALS K. Tsioufis (Athens, GREECE)
D. Collard, T. Brouwer, R. O. Engberink, A. Zwinderman, L. Vogt,
B.-J. van den Born 15.40-15.45 Session evaluation and key learnings
Amsterdam, THE NETHERLANDS G. Parati (Milan, ITALY)
41
MONDAY, APRIL 12 SCIENTIFIC PROGRAMME
15.15-15.30 When and how to look for cerebrovascular FMD? 15.12-15.24 Daily life factors on primordial prevention
A. Persu (Brussels, BELGIUM) E. Lurbe (Valencia, SPAIN)
15.30-15.45 Acute coronary syndrome: when to look for FMD? 15.24-15.36 Ambulatory BP monitoring should be included in
D. Adlam (Leicester, UNITED KINGDOM) pediatric hypertension criteria
E. Wühl (Heidelberg, GERMANY)
15.45-16.00 Discussion
15.36-15.48 Kidney damage in childhood primary hypertension
J. Flynn (Seattle, WA, USA)
15.48-16.00 Discussion
42
MONDAY, APRIL 12 SCIENTIFIC PROGRAMME
15.00-16.00 - ROOM 5
15.18 ASSOCIATION OF HYPERTENSION WITH ALL-CAUSE
Oral Session 6B MORTALITY AMONG HOSPITALIZED PATIENTS WITH COVID-19
E. Rodilla 1, A. Saura 1, I. Jiménez 1, A. Mendizábal 1, A. Pineda-Cantedo 2,
E. Lorenzo-Hernández 2, M. Del Pilar Fidalgo-Montero 3,
COVID-19 AND HYPERTENSION
J.F. López-Cuervo 4, R. Gil-Sánchez 1, E. Rabadán-Pejenaute 5,
Chairpersons: C. Delles (Glasgow, UNITED KINGDOM), L. Abella-Vázquez 6, V. Giner-Galvañ 7, M. Nataya Solís-Marquínez 8,
T. Weber (Wels, AUSTRIA) R. Boixeda 9, A. De La Peña-Fernández 9, F. Javier Carrasco-Sánchez 9,
J.González-Moraleja 9, J. David Torres-Peña 9, M.E. Guisado-Espartero 9,
J. Escobar-Sevilla 9, M. Guzmán-García 9, M.D. Martín-Escalante 9,
15.00 INCREASED CARDIOVASCULAR DEATH RATES IN A Á.L. Martínez-González 9, J.M. Casas-Rojo 9, R. Gómez-Huelgas 2
COVID-19 LOW PREVALENCE AREA 1
Valencia, 2 Málaga, 3 Coslada, 4 Torrevieja, 5 Logroño,
R. Del Pinto, G. Desideri, L. Mammarella, S. Abballe, S. Dell’Anna, 6
Santa Cruz de Tenerife,7 San Juan de Alicante, 8 Avilés, 9 Own City,
S. Cicogna, D. Grassi, S. Sacco, C. Ferri SPAIN
L’Aquila, ITALY
15.24 ROLE OF ACE2 GLYCOSYLATION AND RHO KINASE
15.06 EVIDENCE OF A BLOOD PRESSURE REDUCTION INHIBITION IN THE INFECTIOUS/THERAPEUTIC PROCESS OF
DURING THE COVID-19 ASSOCIATED LOCKDOWN: A PLAUSIBLE COVID-19. INSIGHTS FROM GITELMAN’S AND BARTTER’S
EXPLANATION FOR THE OBSERVED DECLINES IN ACUTE SYNDROMES PATIENTS
CARDIOVASCULAR DISEASES? G. Bertoldi, L. Gianesello, M. Rigato, L. Sgarabotto, L. Calò
N. Girerd 1, C. Meune 2, K. Duarte 1, V. Vercamer 3, M. Lopez-Sublet 2, Padua, ITALY
J.-J. Mourad 4
1
Nancy, 2 Bobigny, 3 Issy les Moulineaux, 4 Paris, FRANCE 15.30 RENIN-ANGIOTENSIN SYSTEM INHIBITORS AND COVID-19:
A SYSTEMATIC REVIEW AND META-ANALYSIS. EVIDENCE FOR
15.12 HYPERTENSION AND RENIN-ANGIOTENSIN SYSTEM SIGNIFICANT GEOGRAPHICAL DISPARITIES
BLOCKERS ARE NOT ASSOCIATED WITH EXPRESSION OF D. Patoulias, A. Katsimardou, K. Stavropoulos, K. Imprialos,
ANGIOTENSIN CONVERTING ENZYME 2 (ACE2) IN THE KIDNEY M. Styliani Kalogirou, M. Doumas
X. Jiang 1, J. Eales 1, D. Scannali 1, A. Nazgiewicz 1, P. Prestes 2, M. Maier 2, Thessaloniki, GREECE
M. Denniff 3, X. Xu 1, S. Saluja 1, W. Wystrychowski 4, J. Zywiec 6,
E. Zukowska-Szczechowska 4, L.M. Burrell 7, A. Greenstein 1, 15.36 HYPERTENSION AND COVID-19: THE POSSIBLE ROLE OF
P. Bogdanski 5, B. Keavney 1, A.P. Morris 1, A. Heagerty 1, N.J. Samani 3, METALLOPROTEINASE-9 IN COVID-19 PATHOPHYSIOLOGY
T.J. Guzik 8, F.J. Charchar 2,3, M. Tomaszewski 1 C. Dávila Mesquita, A.E. Souza do Couto, L. Borges Campos,
1
Manchester, UNITED KINGDOM, 2 Ballarat, AUSTRALIA, 3 Leicester, B.C. Petroski Mora, F. Mestriner, T. Fernandes Vasconcelo,
UNITED KINGDOM, 4 Katowice, 5 Poznan, 6 Zabrze, POLAND, J. Michelon Barbosa, C. Curylofo Corsi, D. Ferro, M. Serra Ribeiro,
7
Melbourne, AUSTRALIA, 8 Glasgow, UNITED KINGDOM M. Gonçalves Menegueti, M. Auxiliadora Martins, C. Becari
Ribeirao Preto, BRAZIL
43
MONDAY, APRIL 12 SCIENTIFIC PROGRAMME
15.00-16.00 - ROOM 6
15.42 IN-HOSPITAL DIURETIC USE IS ASSOCIATED WITH WORSE
OUTCOME IN PATIENTS WITH COVID-19 ISH New Investigator Committee
M. Pengo, G. Stefanini, C. Pivato, D. Soranna, G. Zambra, A. Zambon,
C. Torlasco, G. Bilo, G. Condorelli, G. Parati Award Session
Milan, ITALY Chairpersons: C. Landry (Ottawa, CANADA),
R. Muralitharan (Clayton, AUSTRALIA)
15.48 IMPACT OF COVID-19 LOCKDOWN ON VASCULAR
STIFFNESS TRAJECTORIES IN FRANCE AND GERMANY 15.00 DIFFERENTIAL PREVALENCE AND ASSOCIATIONS OF
R.M. Bruno 1, J.-L. Pepin 2, J.-P. Empana 1, R.-Y. Yang 3, V. Vercamer 3, CHRONIC KIDNEY DISEASE BY FIVE ESTIMATORS IN A SOUTH
P. Jouhaud 3, P. Escorrou 3, P. Boutouyrie 1 AFRICAN POPULATION-BASED STUDY
1
Paris, 2 Grenoble, 3 Issy les Moulineaux, FRANCE N. Peer 1,2, J. George 3, C. Lombard 2, K. Steyn 2, N. Levitt 2,
A.-P. Kengne 1,2
1
Durban, 2 Cape Town, 3 Johannesburg, SOUTH AFRICA
44
MONDAY, APRIL 12 SCIENTIFIC PROGRAMME
16.00-17.00 - AUDITORIUM
15.35 ANGIOTENSIN II-INDUCED ER STRESS RESPONSE Omron Academy Online
CONTRIBUTES TO PROFIBROTIC VSMC PHENOTYPE AND
SUBSEQUENT HYPERTENSIVE ARTERIAL STIFFNESS
INNOVATION IN THE ONLINE EDUCATION ON
S. Cicalese, H. Cooper, K. Preston, T. Kawai, R. Scalia, S. Eguchi
Philadelphia, PA, USA CARDIOVASCULAR DISORDERS IN
COLLABORATION WITH THE ESH
15.42 BLOOD PRESSURE PREVALENCE WITH STRATIFICATION Chairperson: G. Parati (Milan, ITALY)
AND ASSOCIATIONS: A COMMUNITY-BASED STUDY FROM
LONGITUDINAL COHORT HOUSEHOLD SURVEY 2019
N. Chakaraborty 1, K. Chakraborty 2, R. Nath Mitra 1, A. Saha 1, 16.00-16.25 Free, easy to use and up-to-date online education
P. Chatterjee 1, S. Manna 1, D. Mitra 1 platform developed by ESH in collaboration with
1
Kolkata, INDIA, 2 Baltimore, MD, USA OMRON
G. Parati (Milan, ITALY)
15.49 ASSOCIATION OF CHILDHOOD PHYSICAL EXAMINATION
AND LABORATORY PARAMETERS WITH HIGH BLOOD PRESSURE 16.25-16.50 Introducing OMRON Academy online for credible
IN JAPANESE YOUNG ADULTS cardiovascular education courses
T. Azegami 1, K. Uchida 1, F. Arima 1, Y. Sato 2, M. Awazu 3, M. Inokuchi 1, R. Asmar (Paris, FRANCE)
A. Takeda 1, H. Itoh 2, M. Tokumura 1, M. Mori 1
1
Yokohama-Shi, 2 Tokyo, JAPAN 16.50-17.00 Discussion
45
MONDAY, APRIL 12 SCIENTIFIC PROGRAMME
16.00 LECTURE
16.00-16.05 Introduction WHITE COAT AND MASKED HYPERTENSION. OLD AND NEW
A.J. Manolis (Athens, GREECE), PROBLEMS
B. Williams (London, UNITED KINGDOM) G. Mancia (Milan, ITALY)
46
MONDAY, APRIL 12 SCIENTIFIC PROGRAMME
16.00-17.00 - ROOM 3
16.36 TWO-DRUG FIXED-DOSE COMBINATION AS INITIAL
ANTIHYPERTENSIVE TREATMENT STRATEGY CONFERS HIGHER Oral Session 7B
MEDICATION ADHERENCE COMPARED TO MONOTHERAPY
F. Rea 1, L. Savaré 1, G. Corrao 1, G. Mancia 1,2
BIOMARKERS
1
Milan, 2 Monza, ITALY
Chairpersons: H.-P. Marti (Bergen, NORWAY),
16.43 LECTURE A. Januszewicz (Warsaw, POLAND)
THE SPRINT MARATHON: THE RACE GOES ON
S. Oparil (Birmingham, AL, USA) 16.00 ASSOCIATIONS OF RENALASE WITH BLOOD PRESSURE
AND THE RISK OF HYPERTENSION IN CHINESE ADULTS
Y. Wang, K. Gao, C. Chen, Y. Yan, Y. Yuan, K.-K. Wang, J.-W. Hu,
C. Chu, Q. Ma, B.-W. Fu, Y.-Y. Liao, M. Li, Y. Sun, M.-J. He, J.-J. Mu
Xi’an, CHINA
47
MONDAY, APRIL 12 SCIENTIFIC PROGRAMME
16.00-17.00 - ROOM 4
16.28 PLASMA FATTY ACIDS AND THE RISK OF VASCULAR AND
MORTALITY OUTCOMES IN INDIVIDUALS WITH TYPE 2 DIABETES: Joint Session ESH-ISH-BIHS - Young
RESULTS FROM THE ADVANCE STUDY
K. Harris 1, M. Oshima 1,2, N. Sattar 3, P. Wurtz 4, M. Jun 1, P. Welsh 3, investigator Symposium
J. Chalmers 1, M. Woodward 1,5
1
Sydney, AUSTRALIA, 2 Ishikawa, JAPAN, 3 Glasgow, UNITED KINGDOM, DEVELOPING COLLABORATIONS TO FURTHER YOUR
4
Helsinki, FINLAND, 5 Oxford, UNITED KINGDOM CAREER
16.35 IDENTIFICATION OF CANDIDATE BIOMARKERS FOR Chairpersons: P. Christofidou (London, UNITED KINGDOM)
SALT SENSITIVITY OF BLOOD PRESSURE BY INTEGRATED A. Montezano (Glasgow, UNITED KINGDOM)
BIOINFORMATICS ANALYSIS
C. Chen, G. Liu, C. Chu, W. Zheng, J. Hu, Y. Wang, Q. Ma, Y. Yan,
Y. Yuan, Y. Liao, J. Mu 16.00-16.10 Why be a member of ESH/ISH/BIHS as young
Xi’an, CHINA investigators?
L. Faconti (London, UNITED KINGDOM),
16.42 REFERENCE RANGES AND CUT-OFF VALUES FOR B. Wynne (Salt Lake City, GA, GEORGIA)
SIMULTANEOUS MONITORING OF RAS BLOCKER EFFICACY AND
SCREENING FOR SECONDARY HYPERTENSION USING RAAS 16.10-16.20 Interacting with senior delegates at a conference: Do’s
TRIPLE-A PROFILING and don’ts
M. Poglitsch 1, L. Foco 2, M. Gögele 2, P.P. Pramstaller 2, C. Pattaro 2 J.K. Cruickshank (London, UNITED KINGDOM)
1
Vienna, AUSTRIA, 2 Bolzano, ITALY
16.20-16.30 Using my conference presentation to meet
16.49 F-18 FDG PET/CT CAN BE USED AS AN IMAGING collaborators abroad
BIOMARKER FOR REFLECTING SYNTHETIC VASCULAR SMOOTH F. Saladini (Padua, ITALY)
MUSCLE CELL ACTIVITY IN THE ANIMAL MODEL OF VASCULAR
REMODELING DISORDER 16.30-16.40 Making the most of the opportunities from the Society
K. Pahk, C. Joung, S. Kim, W.-K. Kim to forge new connections
Seoul, SOUTH KOREA F. Marques (Melbourne, AUSTRALIA)
48
MONDAY, APRIL 12 SCIENTIFIC PROGRAMME
16.00-17.00 - ROOM 5
16.43 CORRELATION OF ANKLE-BRACHIAL INDEX WITH
Oral Session 7C SEVERITY OF CORONARY ARTERY DISEASE IN PATIENTS
HOSPITALIZED FOR ACUTE MYOCARDIAL INFARCTION
A. Koumelli, K. Tsioufis, K. Konstantinou, E. Mantzouranis, A. Kasiakogias,
MULTIMORBIDITY AND CO-MORBIDITIES
K. Dimitriadis, A. Milkas, D. Konstantinidis, I. Leontsinis, D. Tousoulis
Chairpersons: C. Borghi (Bologna, ITALY), Athens, GREECE
P. van de Borne (Brussels, BELGIUM)
16.50 RELATIONSHIPS BETWEEN ANTI-HYPERTENSIVE DRUGS
AND NOCTURIA: A SYSTEMATIC REVIEW
16.00 ISOLATED SYSTOLIC HYPERTENSION VERSUS COMBINED Y. Akasaki, T. Kubozono, K. Higuchi, M. Ohishi
SYSTOLIC-DIASTOLIC HYPERTENSION AS PREDICTOR OF ATRIAL Kagoshima, JAPAN
FIBRILATION: DATA FROM AN 8-YEAR-FOLLOW-UP STUDY
D. Konstantinidis, K. Tsioufis, I. Liatakis, E. Koutra, I. Leontsinis,
M. Kouremeti, P. Iliakis, N. Karaminas, F. Tatakis, P. Papakonstantinou,
A. Anastasiou, D. Mourtzoukou, E. Siafi, N. Kakouri, M. Dimitriadi,
D. Tousoulis
Athens, GREECE
49
MONDAY, APRIL 12 SCIENTIFIC PROGRAMME
16.00-17.00 - ROOM 6
Workshop
IMMUNITY AND INFLAMMATION IN HYPERTENSION -
FROM BASIC MECHANISMS TO CLINICAL
TRANSLATION
Chairpersons: T. Guzik (Glasgow, UNITED KINGDOM),
E. Schiffrin (Montreal, CANADA)
16.40-17.00 Discussion
E. Schiffrin (Montreal, CANADA),
T. Guzik (Glasgow, UNITED KINGDOM),
G. Lembo (Rome, ITALY),
G. Drummond (Melbourne, AUSTRALIA),
D. Carnevale (Rome, ITALY)
50
TUESDAY, APRIL 13 SCIENTIFIC PROGRAMME
11.00-11.05 Opening
11.00-11.12 Measuring adherance in research and clinical practice: G.S. Stergiou (Athens, GREECE)
any improvement?
M. Burnier (Lausanne, SWITZERLAND) 11.05-11.20 Blood pressure measurement in public places
Y. Li (Shangai, CHINA)
11.12-11.24 Therapeutic inertia: causes and impact against
achievement of optimal treatment 11.20-11.35 Masked hypertension in treated hypertension: the
F.P. Cappuccio (Coventry, UNITED KINGDOM) MASTERS Trial
G. Parati (Milan, ITALY)
11.24-11.36 Adherence, inertia and cardiovascular risk: news from
the Lombardy database 11.35-11.50 Cigarettes smoking and masked hypertension
G. Mancia (Milan, ITALY) D.-Y. Zhang (Shanghai, CHINA)
11.36-11.48 What have we learned about managing non-adherence 11.50-12.00 Discussion and Closing
to antihypertensive treatment from LC-MS/MS-based J. Wang (Shanghai, CHINA)
analyses of blood/urine
M. Tomaszewski (Manchester, UNITED KINGDOM)
11.48-12.00 Discussion
53
TUESDAY, APRIL 13 SCIENTIFIC PROGRAMME
11.45-12.00 Discussion
54
TUESDAY, APRIL 13 SCIENTIFIC PROGRAMME
Workshop Workshop
GLOBAL TRAINING PROGRAMS TO IMPROVE European Council for Cardiovascular Research (ECCR) –
HYPERTENSION CARE: FUNDAMENTAL BUT High blood pressure research council of Australia (HBPRCA)
UNDERAPPRECIATED ASPECT SOME NEW CONCEPTS IN HYPERTENSION
Chairpersons: A. Schutte (Sydney, AUSTRALIA), Chairpersons: M. Schlaich (Perth, AUSTRALIA),
X.-H. Zhang (Urumqi, CHINA) T. Unger (Maastricht, THE NETHERLANDS)
11.00-11.15 Experience of Virtual Academy in central and south 11.00-11.12 Update on estrogens in cardiovascular disease
America M. Barton (Zurich, SWITZERLAND)
P. Ordunez (Washington DC, USA)
11.12-11.24 Sympatho-inhibitory effects of dexmedetomidine
11.15-11.30 Experience of in-person training in China reduces catecholamine requirements to restore target
X.-H. Zhang (Urumqi, CHINA) blood pressure and preserves renal oxygenation and
function in septic acute kidney injury
11.30-11.45 Short videos and a free online course for non- Y.R. Lankadeva (Parkville, AUSTRALIA)
physicians
K. Matsushita (Baltimore, MD, USA) 11.24-11.36 Inhibition of ACE C-domain and neprilysin in a chronic
angiotensin II-dependent mouse model of hypertension
11.45-12.00 Discussion R. Alves-Lopes (Glasgow, UNITED KINGDOM)
11.48-12.00 Discussion
55
TUESDAY, APRIL 13 SCIENTIFIC PROGRAMME
11.00-12.00 - ROOM 6
11.35 IMMUNE CELLS MEDIATED EFFECTS OF SODIUM
Oral Session 8A CHLORIDE ON THE DEVELOPMENT OF VASCULAR INFLAMMATION
AND ABDOMINAL AORTIC ANEURYSM IN ANGIOTENSIN
II-TREATED APOE-KO MICE
INFLAMMATION AND IMMUNITY
J. Stegbauer, M. Yakoub, M. Rahman, L. Hering, S. Potthoff, D. Argov,
Chairpersons: T. Guzik (Glasgow, UNITED KINGDOM), U. Flögel, L. Christian Rump, S. Temme
G.P. Rossi (Padua, ITALY) Düsseldorf, GERMANY
56
TUESDAY, APRIL 13 SCIENTIFIC PROGRAMME
57
TUESDAY, APRIL 13 SCIENTIFIC PROGRAMME
13.12-13.24 CV effects of new antidiabetic drugs: good or bad? 13.15 EFFECTS OF FEBUXOSTAT ON CAROTID INTIMA-MEDIA
H.A.J. Struijker-Boudier (Maastricht, THE NETHERLANDS) THICKNESS IN ASYMPTOMATIC HYPERURICEMIA: A RANDOMIZED
CLINICAL TRIAL (PRIZE)
A. Tanaka 1, I. Taguchi 2, H. Teragawa 3, N. Ishizaka 4, T. Murohara 5,
13.24-13.36 Pheochromocytoma: how to detect, how to manage?
K. Node 1
A. Prejbisz (Warsaw, POLAND) 1
Saga, 2 Koshigaya, 3 Hiroshima, 4 Takatsuki, 5 Nagoya, JAPAN
13.36-13.48 Diuretic induced hyponatremia - pathogenesis and 13.22 OPTIMAL DRUGS FOR MEDICATION REDUCTION:
management SECONDARY ANALYSIS OF THE OPTIMISE MEDICATION
M. Glover (Nottingham, UNITED KINGDOM) REDUCTION TRIAL
J. Sheppard 1, M. Lown 2, J. Burt 3, E. Temple 1, G. Ford 1, R. Hobbs 1,
13.48-14.00 Discussion P. Little 2, J. Mant 3, R. Payne 4, R. McManus 1
1
Oxford, 2 Southampton, 3 Cambridge, 4 Bristol, UNITED KINGDOM
58
TUESDAY, APRIL 13 SCIENTIFIC PROGRAMME
13.00-14.00 - ROOM 3
13.43 STRATIFIED EFFECTS OF BLOOD PRESSURE-LOWERING
TREATMENT ON LONG-TERM BLOOD PRESSURE: A META- Oral Session 9B
ANALYSIS OF INDIVIDUAL-LEVEL DATA OF 334,219 PARTICIPANTS
FROM 50 RANDOMIZED TRIALS
LARGE ARTERIES
D. Canoy 1, E. Copland 1, R. Ramakrishnan 1, A.-C. Pinho-Gomes 1,
M. Nazarzadeh 1, Z. Bidel 1, G. Salimi-Khorshidi 1, M. Woodward 1,2, Chairpersons: C. McEniery (Cambridge, UNITED KINGDOM),
B.R. Davis 3, C.J. Pepine 4, J. Chalmers 2, K. Teo 5, K. Rahimi 1 B. Spronck (New Haven, CT, USA)
1
Oxford, UNITED KINGDOM, 2 Sydney, AUSTRALIA, 3 Houston, TX,
4
Gainesville, FL, USA, 5 Hamilton, Toronto, CANADA
13.00 GENETIC BACKGROUND DOMINATES FIBROTIC AORTIC
13.50 OPTIMAL THRESHOLDS FOR AMBULATORY BLOOD REMODELING DURING ANGIOTENSIN-INDUCED HYPERTENSION
PRESSURE IN PATIENTS WITH HIGH CARDIOVASCULAR RISK IN MICE
H. Jaehyung, L. Chanjoo, K. Hyoeun, C. Kyeong-Hyeon, O. Jaewon, B. Spronck 1,2, A.W. Caulk 1, A.B. Ramachandra 1, S.-I. Murtada 1,
L. Sang-Hak, K. Seok-Min, P. Sungha A. Rojas 1, C.-S. He 1, M.R. Bersi 3, G. Tellides 1, J.D. Humphrey 1
Seoul, SOUTH KOREA 1
New Haven, CT, USA, 2 Maastricht, THE NETHERLANDS,
3
Nashville, TN, USA
59
TUESDAY, APRIL 13 SCIENTIFIC PROGRAMME
60
TUESDAY, APRIL 13 SCIENTIFIC PROGRAMME
14.00-15.00 - AUDITORIUM
13.28 IS BP LOAD ON AMBULATORY MONITORING A PREDICTOR
OF TARGET ORGAN DAMAGE IN YOUTH? THE SHIP AHOY STUDY May Measurement Month
G. Hamdani 1, M. Ferguson 2, M. Lande 3, K. Meyers 4, J. Samuels 5,
J.T. Flynn 6, E.M. Urbina 7 Chairpersons: A.F. Dominiczak (Glasgow, UNITED KINGDOM),
1
Petah Tikva, ISRAEL, 2 Boston, MA, 3 Rochester, NY, 4 Philadelphia, PA, A. Schutte (Sydney, AUSTRALIA)
5
Houston, TX, 6 Seattle, WA, 7 Cincinnati, PH, USA
13.35 KEEP THE FIRST READING: AN ARGUMENT FOR THE 14.00-14.10 Rationale, methods, key results 2017 & 2018
IMPORTANCE OF THE FIRST OFFICE BLOOD PRESSURE READING N.R. Poulter (London, UNITED KINGDOM)
IN CHILDREN
R. Myette, J. Feber 14.10-14.25 MMM19 global results
Ottawa, CANADA T. Beaney (London, UNITED KINGDOM)
13.42 TRENDS IN OFFICE AND AMBULATORY BP ACROSS 14.25-14.35 Summary of MMM posters and abstracts
PEDIATRIC AGE G.S. Stergiou (Athens, GREECE)
E. Lurbe 1,2, J. Alvarez 1,2, M.I. Torro 1,2, J. Redon 1,2, F. Aguilar 1,2,
P. Redon 1,2 14.35-14.55 Regional and national presentations
1
Madrid, 2 Valencia, SPAIN China - J. Wang (Shanghai, CHINA)
India - M. Patil (Pune, INDIA)
13.49 HYPERTENSION PHENOTYPES IN YOUNG INDIVIDUALS Argentina - M. Salazar (La Plata, ARGENTINA)
DEFINED BY OFFICE, AMBULATORY AND HOME BLOOD Kenya - E. Ogola (Nairobi, KENYA)
PRESSURE MEASUREMENT: PREVALENCE AND ASSOCIATION
WITH TARGET ORGAN DAMAGE 14.55-14.58 MMM21
M.E. Zeniodi, A. Ntineri, A. Kollias, G. Servos, I. Moyssakis, A. Destounis, N.R. Poulter (London, UNITED KINGDOM)
A. Vazeou, G. S. Stergiou
Athens, GREECE 14.58-15.00 Closing remarks
A.F. Dominiczak (Glasgow, UNITED KINGDOM)
61
TUESDAY, APRIL 13 SCIENTIFIC PROGRAMME
14.00-15.00 - ROOM 1
14.28 PREVALENCE OF PRIMARY ALDOSTERONISM AND
Oral Session 10A HYPOKALEMIA IN 5,100 PATIENTS REFERRED TO A TERTIARY
HYPERTENSION UNIT
J. Burrello 1, S. Monticone 1, I. Losano 1, G. Cavaglia’ 1, F. Buffolo 1,
ENDOCRINE HYPERTENSION
M. Tetti 1, M. Covella 1, F. Rabbia 1, F. Veglio 1, B. Pasini 1, T.A. Williams 1,2,
Chairpersons: D. Hering (Gdansk, POLAND) P. Mulatero 1
P. Mulatero (Turin, ITALY) 1
Turin, ITALY, 2 Munich, GERMANY
62
TUESDAY, APRIL 13 SCIENTIFIC PROGRAMME
14.45-15.00 Discussion
63
TUESDAY, APRIL 13 SCIENTIFIC PROGRAMME
14.00-14.15 Risco Vascular e COVID-19 em África/Vascular risk and 14.00-14.20 What’s new in large and medium-sized arteries
COVID-19 in Africa R.M. Bruno (Paris, FRANCE)
A. Damasceno (Maputo, MOZAMBIQUE)
14.20-14.40 What’s new in small arteries and microcirculation
14.15-14.30 O que há de novo na Diretriz Brasileira de Hipertensão C. Stehouwer (Maastricht, THE NETHERLANDS)
2020/What’s new on 2020 Brazilian Hypertension
Guidelines 14.40-15.00 Discussion
W. Sebba-Barroso (Goiania, BRAZIL)
14.45-15.00 Discussion
64
TUESDAY, APRIL 13 SCIENTIFIC PROGRAMME
14.00-14.15 Pro - We are doing well, there is no need to improve 15.00-15.10 Welcome and Objectives
methods R. Kreutz (Berlin, GERMANY),
P.K. Whelton (New Orleans, LA, USA) G. Mancia (Milan, ITALY),
G.S. Stergiou (Athens, GREECE)
14.15-14.30 Against - We are not doing well, there is a need to
improve methods 15.10-15.30 GENERAL ISSUES
J. Filipovsky (Pilsen, CZECH REPUBLIC) Chairpersons: K. Kario (Tochigi, JAPAN),
M.G. Myers (Toronto, CANADA)
14.30-14.45 Discussion
15.10-15.20 BP measuring devices - arm/wrist cuff and cuffless
G.S. Stergiou (Athens, GREECE)
Comments
G. Head (Melbourne, AUSTRALIA)
65
TUESDAY, APRIL 13 SCIENTIFIC PROGRAMME
15.40-15.50 Ambulatory BP monitoring 16.30-16.40 How to detect white coat and masked hypertension in
E. O’Brien (Dublin, IRELAND) clinical practice?
Comments K. Kario (Tochigi, JAPAN),
E. Manios (Athens, GREECE) R. McManus (Oxford, UNITED KINGDOM),
J. Sharman (Hobart, AUSTRALIA)
15.50-16.00 Home BP monitoring and telemonitoring
G. Parati (Milan, ITALY) 16.40-16.50 How to detect non-dippers in clinical practice?
Comments A. De la Sierra (Barcelona, SPAIN),
S. Omboni (Varese, ITALY) A. Kollias (Athens, GREECE),
J. Wang (Shanghai, CHINA)
16.00-16.10 OTHER BP MEASUREMENT METHODS
Chairpersons: E. Dolan (Dublin, IRELAND), 16.50-17.00 Conclusions and Closing
T. Ohkubo (Sendai, JAPAN) E. O’Brien (Dublin, IRELAND),
G. Parati (Milan, ITALY)
16.00-16.10 BP measurement in pharmacies/kiosks
R. McManus (Oxford, UNITED KINGDOM)
Comments
K. Asayama (Tokyo, JAPAN)
66
TUESDAY, APRIL 13 SCIENTIFIC PROGRAMME
15.00-16.00 - ROOM 1
15.28 BLOOD PRESSURE LOWERING EFFECTS AND SAFETY
Oral Session 11A OF ESEXERENONE, NEWLY AVAILABLE MINERALOCORTICOID
RECEPTOR BLOCKER
F. Satoh, R. Morimoto, Y. Tezuka, K. Omata, H. Yamanami, Y. Ono, S. Ito
RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
Sendai, JAPAN
Chairpersons: A. Persu (Brussels, BELGIUM),
R. Wainford (Boston, MA, USA) 15.35 TELMISARTAN IMPROVES MYOCARDIAL REMODELING IN
RATS WITH HYPERTENSIVE LEFT VENTRICULAR HYPERTROPHY
THROUGH INHIBITING LEPTIN AUTOCRINE INDUCED BY ANGII
15.00 DOCA-SALT DIMINISHES BRAIN RAS ACTIVITY IN AND ACTIVATING PPAR GAMMA
PARALLEL WITH PLASMA AND RENAL RAS ACTIVITY – NO H. Chen, M. Li, L. Liu, D. Zhu, G. Tian
EVIDENCE FOR SELECTIVE BRAIN RAS ACTIVATION Xi’an, CHINA
E. Uijl 1, L. Ren 1, K.M. Mirabito Colafella 2, M. Poglitsch 3, O. Domenig 3,
I. Zlatev 4, J.B. Kim 4, S. Huang 4, L. Melton 4, D. Foster 4, A.H. Jan Danser 1 15.42 PROXIMAL TUBULE-SPECIFIC DELETION OF AT1A
1
Rotterdam, THE NETHERLANDS, 2 Melbourne, AUSTRALIA, 3 Vienna, RECEPTORS ATTENUATES ANGIOTENSIN II-INDUCED
AUSTRIA, 4 Cambridge, MA, USA
HYPERTENSION BY INCREASING GLOMERULAR FILTRATION
AND THE PRESSURE-NATRIURESIS RESPONSE
15.07 ESTABLISHMENT OF A NEW SPECIFIC HIGH SENSITIVITY
MEASUREMENT SYSTEM FOR SOLUBLE ANGIOTENSIN IV X. Li 1, A. Leite 1, X. Zheng 2, C. Zhao 2, J. Zhuo 1
RECEPTOR
1
New Orleans, LA, USA, 2 Nanning, CHINA
T. Konoshita 1, S. Azuma 1, M. Sugiyama 1, M. Furutani 1, S. Kaeriyama 1,
R. Saito 1, S. Sato 1, M. Imagawa 1, Y. Zenimaru 1, J. Suzuki 1, M. Fujii 1, 15.49 RECEPTOR INTERACTING MOLECULE ATRAP AS
Y. Makino 2 MODULATOR OF RENAL SODIUM HANDLING AND PATHOLOGICAL
1
Fukui, 2 Tsuruga, JAPAN BLOOD PRESSURE RESPONSE
K. Tamura, T. Yamaji, S. Kinguchi, R. Kobayashi, K. Azushima, K. Uneda,
15.14 DISTRIBUTION OF RENIN-ANGIOTENSIN-ALDOSTERONE K. Haruhara, T. Kanaoka, S. Urate, E. Abe, S. Tanaka, T. Ishii, T. Kumagai,
SYSTEM (RAAS) BIOMARKERS IN TREATED HYPERTENSIVE A. Yamashita, H. Wakui
INDIVIDUALS FROM THE GENERAL POPULATION: THE CHRIS Yokohama, JAPAN
STUDY
L. Foco 1, M. Poglitsch 2, M. Gögele 1, P.P. Pramstaller 1, C. Pattaro 1
1
Bolzano, ITALY, 2 Vienna, AUSTRIA
67
TUESDAY, APRIL 13 SCIENTIFIC PROGRAMME
15.45-16.00 Discussion
Q. Mukhtar (Atlanta, GA, USA), M.H. Olsen (Holbæk,
DENMARK), N.R. Poulter (London, UNITED KINGDOM)
68
TUESDAY, APRIL 13 SCIENTIFIC PROGRAMME
15.50-16.00 Discussion
69
TUESDAY, APRIL 13 SCIENTIFIC PROGRAMME
15.00-16.00 - ROOM 6
Oral Session 11B 15.28 DNA REPAIR DEFECT IN SMOOTH MUSCLE CELL
REPRODUCES FEATURES OF AGE-RELATED VASCULAR DISEASE
IN MICE
AGEING
E. Ataei Ataabadi 1, K. Golshiri 1, R. De Vries 1, G.L. Snyder 2, L. Zhang 2,
Chairpersons: A. Benetos (Nancy, FRANCE), P. Li 2, R.E. Davis 2, A.H.J. Danser 1, A.J.M. Roks 1
B. Wynne (Salt Lake City, UT, USA) 1
Rotterdam, THE NETHERLANDS, 2 New York, NY, USA
70
TUESDAY, APRIL 13 SCIENTIFIC PROGRAMME
71
TUESDAY, APRIL 13 SCIENTIFIC PROGRAMME
16.00-17.00 - ROOM 3
16.28 87 RARE VARIANTS ASSOCIATED WITH BLOOD PRESSURE
Oral Session 12A IN META-ANALYSIS OF ~1.32 MILLION INDIVIDUALS
E. Feofanova
Houston, TX, USA
BIG DATA AND e-HEALTH
Chairpersons: H. Itoh (Tokyo, JAPAN), 16.35 MACHINE LEARNING CLUSTERING FOR BLOOD PRESSURE
M. Viigimaa (Tallinn, ESTONIA) VARIABILITY: VALIDATION FROM THE SPRINT TO THE HONG KONG
COMMUNITY COHORT
K. Tsoi 1, N. Chan 1, K. Yiu 1, S. Poon 2, K. Ho 3, B. Lin 4
16.00 COMPARATIVE EFFECTIVENESS OF 1
Shatin, HONG KONG, 2 Sydney, AUSTRALIA, 3 Vancouver, CANADA,
HYDROCHLOROTHIAZIDE VERSUS CHLORTHALIDONE ON 4
California, UNITED STATES MINOR OUTLYING ISLANDS
CARDIAC, RENAL AND ELECTROLYTE EVENTS BY EGFR STAGE
C. Edwards, W. Petrcich, G. Hundemer, E. Clark, G. Knoll, M. Ruzicka, 16.42 LECTURE
E. Rhodes, K. Burns, M. Sood PERSONALIZED APPROACHES TO HYPERTENSION:
Ottawa, CANADA OPPORTUNITIES AND OBSTACLES
D. Arnett (Lexington, KY, USA)
16.07 MACHINE LEARNING BASED MODELS FOR PREDICTING
WHITE-COAT AND MASKED PATTERNS OF BLOOD PRESSURE
S. Lip 1, L. McCallum 1, S. Reddy 2, N. Chandrasekaran 3, S. Tule 3,
R.K. Bhaskar 3, S. Padmanabhan 1
1
Glasgow, UNITED KINGDOM, 2 Geelong, 3 Canberra, AUSTRALIA
72
TUESDAY, APRIL 13 SCIENTIFIC PROGRAMME
16.00-17.00 - ROOM 4
16.43 PULSE WAVE REFLECTION AND GENDER DIFFERENCE IN
Oral Session 12B OBESE INDIVIDUALS
Z. Junli 1, C. Huijuan 1, A. Audrey 2, A. Alberto 2, M. Orourke 2
1
Shanghai, CHINA, 2 Sydney, AUSTRALIA
OBESITY AND METABOLIC SYNDROME
Chairpersons: A.J. Manolis (Athens, GREECE), 16.50 THE ASSOCIATION OF CALF CIRCUMFERENCE AND ALL-
F. Marques (Melbourne, AUSTRALIA) CAUSE, CARDIOVASCULAR AND CEREBROVASCULAR MORTALITY:
RESULTS FROM THE NATIONAL HEALTH AND NUTRITION
EXAMINATION SURVEYS
16.00 LECTURE J. Huang, L. Liu, C. Chen, Y. Huang, G. Shen, Y. Yu, Y. Feng
MICROBES AND METABOLITES: WHAT IS THE PRESSURE? Guangzhou, CHINA
B. Joe (Toledo, OH, USA)
73
TUESDAY, APRIL 13 SCIENTIFIC PROGRAMME
16.00-17.00 - ROOM 5
16.28 DIETARY INFLUENCE OF SYSTOLIC AND DIASTOLIC
Oral Session 12C BLOOD PRESSURE IN THE TWINSUK COHORT
P. Louca 1, S.E. Berry 1, T.D. Spector 1, S. Padmanabhan 2, C. Menni 1
1
London, 2 Glasgow, UNITED KINGDOM
BLOOD PRESSURE VARIABILITY
Chairpersons: G. Grassi (Milan, ITALY), 16.35 SEASONAL VARIATION OF MASKED UNCONTROLLED
J. Wang (Shanghai, CHINA) NOCTURNAL HYPERTENSION MEASURED BY NIGHTIME HOME
BLOOD PRESSURE: THE J-HOP NOCTURNAL BLOOD PRESSURE
STUDY
16.00 INTENSIVE TREATMENT IS SUITABLE FOR PATIENTS WITH K. Narita, S. Hoshide, K. Kario
LOW LEVEL OF BLOOD PRESSURE VARIABILITY: A SECONDARY 1
Shimotsuke, 2 Karatsu, JAPAN
ANALYSIS OF SPRINT
K. Tsoi, K. Yiu, K. Sit, E. Lee, S. Wong 16.42 FIRST RESULTS OF THE NEW HUNGARIAN HYPERTENSION
Shatin, HONG KONG REGISTRY: SEASONAL CHANGES OF BLOOD PRESSURE VALUES
D. Páll 1, J. Nemcsik 2, N. Habony 2, C. Farsang 2, G. Ábrahám 3, A. Simon 4,
16.07 DIPPING PATTERN AND SHORT-TERM BLOOD PRESSURE B. Benczúr 5, Z. Járai 2
VARIABILITY ARE STRONGER PREDICTORS OF CARDIOVASCULAR 1
Debrecen, 2 Budapest, 3 Szeged, 4 Balatonfüred, 5 Szekszárd, HUNGARY
EVENTS THAN AVERAGE 24-HOUR BLOOD PRESSURE IN
HYPERTENSION OF THE YOUNG 16.49 A NOVEL DEFINITION, EARLY EVENING ELEVATED BLOOD
P. Palatini 1, P. Reboldi 2, F. Saladini 1, F. Angeli 2, L. Mos 3, C. Fania 1, PRESSURE, HAS A HIGH PREVALENCE RATE ACCORDING TO
A. Mazzer 4, O. Vriz 3, P. Verdecchia 2 AMBULATORY BLOOD PRESSURE MONITORING
1
Padua, 2 Perugia, 3 San Daniele del Friuli, 4 Vittorio Veneto, ITALY Z. Ma, Y. Zhao, X. Lu, F. Yang, Y. Chen, N. Sun
Beijing, CHINA
16.14 SEASONAL VARIATION OF NIGHTTIME HOME BLOOD
PRESSURE AND ITS ASSOCIATION WITH TARGET ORGAN
DAMAGE: THE J-HOP NOCTURNAL BLOOD PRESSURE STUDY
K. Narita, S. Hoshide, K. Kario
1
Shimotsuke, 2 Karatsu, JAPAN
74
TUESDAY, APRIL 13 SCIENTIFIC PROGRAMME
16.00-17.00 - ROOM 6
Workshop
HYPERTENSIVE EMERGENCIES MANAGEMENT
Chairpersons: J. Brguljan (Ljubljana, SLOVENIA),
L. Ghiadoni (Pisa, ITALY)
16.40-17.00 Discussion
75
WEDNESDAY, APRIL 14 SCIENTIFIC PROGRAMME
11.32-11.47 Pulmonary effects of electronic cigarettes: vaping- 11.32-11.40 Incorporating health care systems and providers in the
associated pulmonary disease call
M. Chaumont (Brussels, BELGIUM) V.S. Ram (Hyderabad, INDIA)
78
WEDNESDAY, APRIL 14 SCIENTIFIC PROGRAMME
Workshop Workshop
ENVIRONMENTAL POLLUTION AND HYPERTENSION CVD DETECTION, PREVENTION AND CONTROL IN
Chairpersons: D. Prabhakaran (Gurugram, INDIA), LOW- AND MIDDLE-INCOME COUNTRIES: FIELD
M. Rajzer (Krakov, POLAND) EPIDEMIOLOGY TRAINING PROGRAM (FETP)
STORIES FROM THE FIELD
Chairpersons: Q. Mukhtar (Atlanta, GA, USA),
11.00-11.20 Environmental pollution and hypertension
A. Moran (New York, NY, USA)
D. Prabhakaran (Gurugram, INDIA)
11.16-11.18 Discussion
11.25-11.27 Discussion
79
WEDNESDAY, APRIL 14 SCIENTIFIC PROGRAMME
11.00-12.00 - ROOM 4
11.27-11.34 Assessing service availability and readiness of health
facilities to offer hypertension diagnosis services in Oral Session 13A
Wakiso District, Uganda
J. Nanono (Kampala, UGANDA)
LIFESTYLE CHANGES/LIPIDS/SALT
11.34-11.36 Discussion Chairpersons: P. López-Jaramillo (Bucaramanga, COLOMBIA),
J. Polonia (Porto, PORTUGAL)
11.36-11.43 FETP Resident/Small Grant Recipient
A. Musyani (Dar es Salaam, TANZANIA)
11.00 HIGH SODIUM INTAKE INDUCES A CATABOLIC STATE
11.43-11.45 Discussion VIA GLOMERULAR HYPERFILTRATION AND ENHANCED
GLOMERULOTUBULAR BALANCE IN PATIENTS WITH ESSENTIAL
11.45-12.00 General Discussion HYPERTENSION
G. Rossitto 1, G. Maiolino 2, S. Lerco 2, G. Ceolotto 2, G. Blackburn 1,
S. Mary 1, G. Antonelli 2, C. Berton 2, V. Bisogni 2, M. Cesari 2, T.M. Seccia 2,
L. Lenzini 2, A. Montezano 1, R. Touyz 1, M.C. Petrie 1, R. Daly 1, P. Welsh 1,
M. Plebani 2, G.P. Rossi 2, C. Delles 1
1
Glasgow, UNITED KINGDOM, 2 Padua, ITALY
11.00-13.00 - ROOM 5
11.28 ASSESSING THE EFFICACY OF A 90 DAY GLUTEN-
FREE DIET ON CHANGE IN WEIGHT AND ANTHROPOMETRY IN Live Session
HYPERTENSIVE MALES
M. Patil, V. Patil
BASICS OF RENAL ULTRASOUND IN HYPERTENSIVE
Pune, INDIA
PATIENTS. AN INITIATIVE OF THE “ESH-SIEMENS
11.35 REDUCTION OF ALCOHOL CONSUMPTION CAN DECREASE EDUCATIONAL IMAGING PROGRAM”
HOME MORNING BLOOD PRESSURE IN MALE HYPERTENSIVE Chairpersons: A. Januszewicz (Warsaw, POLAND),
PATIENTS - OSAKE STUDY A. Persu (Brussels, BELGIUM),
Y. Akagi 1, M. Kabayama 1, M. Tamatani 2, J. Tomita 3, S. Takiuchi 4, M. Pruijm (Lausanne, SWITZERLAND)
K. Yamamoto 1,4, K. Sugimoto 1, H. Rakugi 1, K. Kamide 1
1
Suita, 2 Osaka, 3 Toyonaka, 4 Takarazuka, JAPAN
11.00-11.15 Technical basics of renal ultrasound and normal
11.42 LECTURE findings
BLOOD PRESSURE AND CARDIOVASCULAR RISK: A POPULATION- S. Arampatzis (Bern, SWITZERLAND)
BASED PERSPECTIVE
R. Collins (Oxford, UNITED KINGDOM) 11.15-11.30 Common abnormalities of the urogenital tract (renal
masses, nephrolithiasis, hydronephrosis)
M. Pruijm (Lausanne, SWITZERLAND)
81
WEDNESDAY, APRIL 14 SCIENTIFIC PROGRAMME
12.35-13.00 Discussion
82
WEDNESDAY, APRIL 14 SCIENTIFIC PROGRAMME
Workshop Meet-the-expert
NUTRITION, MICROBIOMA AND CARDIOVASCULAR HOW TO DO A GOOD META-ANALYSIS OF OUTCOME
RISK RANDOMIZED TRIALS IN HYPERTENSION?
Chairpersons: F.P. Cappuccio (Warwick, UNITED KINGDOM), Chairpersons: B. Carlberg (Umeå, SWEDEN),
T. Unger (Maastricht, THE NETHERLANDS) G. Mancia (Milan, ITALY)
12.00-12.20 Microbiome and cardiovascular risk: the gut-heart axis? 12.00-12.20 Which trials to include and exclusion criteria
C. Reinhardt (Mainz, GERMANY) C. Thomopoulos (Athens, GREECE)
12.20-12.40 Plant-based diets and cardiovascular risk: population- 12.20-12.40 How to clinically report the synthesis and how to avoid
based evidence of benefit? mistakes?
B. Kappel (Aachen, GERMANY) M. Brunström (Umeå, SWEDEN)
83
WEDNESDAY, APRIL 14 SCIENTIFIC PROGRAMME
12.00-13.00 - ROOM 4
12.28 ASSESSMENT OF CARDIOVASCULAR EVENTS IN
Oral Session 14A HYPERTENSIVE PATIENTS AT RISK FOR HEART FAILURE USING
GERIATRIC NUTRITIONAL RISK INDEX
T. Hashizume 1, M. Arita 2
ATRIAL FIBRILLATION AND HEART FAILURE 1
Tanabe, 2 Wakayama, JAPAN
Chairpersons: S.E. Kjeldsen (Oslo, NORWAY),
A. Prejbisz (Warsaw, POLAND) 12.35 CLINICAL AND ECHOCARDIOGRAPHIC FEATURES OF
PATIENTS WITH HEART FAILURE WITH MID-RANGE EJECTION
FRACTION COMPARED TO REDUCED AND PRESERVED
12.00 BLOOD PRESSURE LOWERING TREATMENT FOR M. Biolcati, A. Maloberti, S. Bianchi, V. Giani, C. Pellegrinelli, U. Ceratti,
PREVENTION OF CARDIOVASCULAR EVENTS IN PATIENTS WITH O. Belli, F. Casadei, F. Musca, P. Sormani, G. Santambrogio, F. Spanò,
ATRIAL FIBRILLATION: AN INDIVIDUAL-PARTICIPANT DATA B. de Chiara, C. Giannattasio, A. Moreo
META-ANALYSIS Milan, ITALY
A.C. Pinho-Gomes 1, L. Azevedo 3, E. Copland 1, D. Canoy 1,2,
M. Nazarzadeh 1, R. Ramakrishnan 1,2, E. Berge 4, J. Sundstrom 5, 12.42 EFFECT OF BLOOD PRESSURE OPTIMISATION ON
D. Kotecha 6, M. Woodward 1,2, K. Rahimi 1 ENDOTHELIAL FUNCTION IN PATIENTS WITH ATRIAL FIBRILLATION
1
Oxford, UNITED KINGDOM, 2 Sydney, AUSTRALIA, 3 Porto, PORTUGAL, AND HYPERTENSION
4
Tromson, NORWAY, 5 Uppsakla, SWEDEN, 6 Birmingham, UNITED
A.A. Khan 1, G.N. Thomas 1, G. Lip 2
KINGDOM 1
Birmingham, 2 Liverpool, UNITED KINGDOM
12.07 EFFECT OF RENAL DENERVATION ON ATRIAL
12.49 BLOOD PRESSURE AT ADMISSION PREDICTS 1-YEAR
FIBRILLATION (ERDAF)
P. Papakonstantinou, D. Konstantinidis, I. Leontsinis, P. Iliakis, K. Tsioufis OUTCOMES OF PATIENTS HOSPITALIZED FOR HEART FAILURE
Athens, GREECE X. Huang, J. Liu, S. Hu, J. Li
Beijing, CHINA
12.14 GENETIC SUSCEPTIBILITY, ELEVATED BLOOD PRESSURE
AND RISK OF ATRIAL FIBRILLATION
M. Nazarzadeh 1, A.-C. Pinho-Gomes 1, Z. Bidel 1, D. Canoy 1,2,
A. Dehghan 3, K. Smith Byrne 1, D.A. Bennett 1, G.D. Smith 4, K. Rahimi 1
1
Oxford, UNITED KINGDOM, 2 Sydney, AUSTRALIA, 3 London,
4
Bristol, UNITED KINGDOM
13.15-13.30 Physiology - ventricular - vascular interaction 13.15 NATIONWIDE SPATIOTEMPORAL TRENDS IN BLOOD
E. Agabiti Rosei (Brescia, ITALY) PRESSURE AND THE ATTRIBUTABLE CARDIOVASCULAR BURDEN
FROM 2005 TO 2018: A POOLED ANALYSIS OF 13.1 MILLION
13.30-13.45 Treatment PARTICIPANTS IN CHINA
B. Williams (London, UNITED KINGDOM) Y. Kang, X. Wang, P. Yin, Z. Chen, L. Jiang, W. Dong, L. Zhang, C. Zheng,
M. Zhou, Z. Wang, R. Gao
13.45-14.00 Discussion Beijing, CHINA
85
WEDNESDAY, APRIL 14 SCIENTIFIC PROGRAMME
13.00-14.00 - ROOM 2
13.36 HOW MANY ADDITIONAL PHYSICIANS ARE NEEDED FOR
HYPERTENSION TREATMENT IN INDIA? Oral Session 15B
M. Marklund 1, M. Marklund 1,2, D. Neupane 3, J.H.Y. Wu 1, B. Neal 1,4,
K. Matsushita 3, L.J. Appel 3
BLOOD PRESSURE MEASUREMENT
1
Sydney, AUSTRALIA, 2 Boston, MA, 3 Baltimore, MD, USA,
4
London, UNITED KINGDOM Chairpersons: A. Mihailidou (Kensington, AUSTRALIA),
G.S. Stergiou (Athens, GREECE)
13.43 BLOOD PRESSURE TRAJECTORIES FROM CHILDHOOD
TO YOUTH AND ARTERIAL STIFFNESS IN ADULTHOOD: A 30-YEAR
LONGITUDINAL FOLLOW-UP STUDY 13.00 STRIDE BP REVIEW OF PUBLISHED EVIDENCE ON
C. Chu, Y. Wang, J. Mu ACCURATE BLOOD PRESSURE MEASURING DEVICES
Xi’an, CHINA G.S. Stergiou 1, E. O’Brien 2, M. Myers 3, P. Palatini 4, A. Menti 1, A. Kollias
1
, G. Parati 5
13.50 24-H-AMBULATORY BLOOD PRESSURE IN SUB- 1
Athens, GREECE, 2 Dublin, IRELAND, 3 Toronto, CANADA, 4 Padua,
SAHARAN AFRICA: PREVALENCE OF WHITE COAT OR MASKED 5
Milan, ITALY
HYPERTENSION AND DISRUPTED DIPPING PATTERNS IN HIV+
PATIENTS ON ANTIRETROVIRAL THERAPY 13.07 ARTERIAL HYPERTENSION RISK PREDICTION IN
P. Kasper 1, S. Phiri 2, T. Chaweza 2, H. Tweya 2, B. Mwagomba 2, CONDITIONS OF ROTATIONAL SHIFTWORK IN THE ARCTIC
A. Muula 2, A. Nhlema 2, J. Chiwoko 2, F. Neuhann 7, H.-M. Steffen 1,8 N. Shurkevich 1, A. Vetoshkin 2, L. Gapon 1, A. Simonyan 1
1
Cologne, GERMANY, 2 Lilongwe, MALAWI, 3 Lilongwe, MALAWI, 1
Tyumen, 2 Yamburg, RUSSIA
4
Seattle, WA, 5 Chapel Hill, NC, USA, 6 Lilongwe, MALAWI,
7
Heidelberg, GERMANY, 8 Cologne, GERMANY 13.14 CLINICAL CHARACTERISTICS IN THE PATIENTS WITH
MASKED UNCONTROLLED NOCTURNAL HYPERTENSION
MEASURED BY NIGHTIME HOME BLOOD PRESSURE
MONITORING: THE J-HOP NOCTURNAL BP STUDY
K. Narita, S. Hoshide, K. Kario
1
Shimotsuke, 2 Karatsu, JAPAN
86
WEDNESDAY, APRIL 14 SCIENTIFIC PROGRAMME
13.00-14.00 - ROOM 3
13.28 ASSOCIATION OF FATAL AND NONFATAL
CARDIOVASCULAR OUTCOMES WITH 24 HOUR MEAN ARTERIAL Oral Session 15C
PRESSURE
J. Melgarejo 1, W.-Y. Yang 1, L. Thijs 1, Y. Li 2, K. Asayama 3, T. Hansen 4,
PRIMARY ALDOSTERONISM
M. Kikuya 3, T. Ohkubo 3, E. Dolan 5, K. Stolarz-Skrzypek 6, Q.-F. Huang 2,
V. Tikhonoff 7, S. Malyutina 8, E. Casiglia 7, L. Lind 8, E. Sandoya 9, Chairpersons: A. Januszewicz (Warsaw, POLAND),
J. Filipovský 10, N. Gilis-Malinowska 6, K. Narkiewicz 6, K. Kawecka-Jaszcz 6, F.H. Shmouni (Bethesda, MD, USA)
J. Boggia 9, J.-G. Wang 2, Y. Imai 3, T. Vanassche 1, P. Verhamme 1,
S. Janssens 1, E.O. Brien 5, G.E. Maestre 10, J. A. Staessen 1, Z.-Y. Zhang 1
1
Leuven, BELGIUM, 2 Shanghai, CHINA, 3 Tokyo, JAPAN, 13.00 RELATIONSHIP BETWEEN THE HYPOTHALMIC-PITUITARY-
4
Tokyo, DENMARK, 5 Capital region of Denmark, IRELAND, ADRENOCORTICAL AXIS ACTIVITY AND THE CHARACTERISTICS
6
Krakow and Gdansk, POLAND, 7 Padova, ITALY, 8 Russia and Sweden, OF ALDOSTERONE-PRODUCING ADENOMAS
ITALY, 9 Montevideo, URUGUAY, 10 Texas, TX, USA M. Thuzar, Y.-C. Lo, Z. Guo, W. Inder, M. Stowasser
Brisbane, AUSTRALIA
13.35 THE RELATIONSHIP BETWEEN CIRCADIAN RHYTHM OF
BLOOD PRESSURE AND LEFT ATRIAL PHASIC FUNCTION IN 13.07 IS POSTOPERATIVE SUBSTITUTION WITH
HYPERTENSION HYDROCORTISONE NECESSARY AFTER ADRENALECTOMY FOR
Y. Liu, Y. Zhao, Q. Sun, Y. Lu, Y. Zhang, W. Song, Y. Cheng, T. Cong, PRIMARY ALDOSTERONISM?
Y. Jiang T. Zelinka, O. Petrak, D. Michalsky, K. Novak, J. Widimsky Jr.
Dalian, CHINA Praha, CZECH REPUBLIC
13.42 MORNING BLOOD PRESSURE SURGE POWER IS A BETTER 13.14 ABDOMINAL AORTIC CALCIFICATION IN ALDOSTERONE
PREDICTOR OF CARDIOVASCULAR DEATH OR EVENTS IN THE PRODUCING ADENOMA AND IDIOPATHIC HYPERALDOSTERONISM
OHASAMA POPULATION THAN PRE-AWAKE VERSUS POST-AWAKE Y. Shibayama, N. Wada, S. Baba, S. Obara, H. Sakai, H. Usubuchi,
MEASURES S. Terae, H. Kameda, A. Nakamura, T. Atsumi
G. Head 1, Y. Sata 1, T. Ohkubo 2,3, M. Kikuya 2, Y. Imai 3, E. Lukoshkova 4 Sapporo, JAPAN
1
Melbourne, AUSTRALIA, 2 Tokyo, 3 Sendai, JAPAN, 4 Moscow, RUSSIA
13.21 BIOCHEMICAL, HISTOPATHOLOGICAL, AND GENETIC
13.49 INVESTIGATING THE ADHERENCE TO THE 5-MINUTE CHARACTERIZATION OF POSTURE RESPONSIVE AND
RESTING INSTRUCTION BEFORE SELF-MEASURING HOME BLOOD UNRESPONSIVE ALDOSTERONE-PRODUCING ADENOMAS
PRESSURE USING ACCELEROMETER-BASED PHYSICAL ACTIVITY Z. Guo 1, K. Nanba 2,3, B.C. McWhinney 1, J.P. Ungerer 1, M. Wolley 1,
DATA R.D. Gordon 1, W.E. Rainey 2, M. Stowasser 1
R. de Heus, C. Maasakkers, J. Claassen 1
Brisbane, AUSTRALIA, 2 Ann Arbor, ML, USA, 3 Kyoto, JAPAN
Nijmegen, THE NETHERLANDS
87
WEDNESDAY, APRIL 14 SCIENTIFIC PROGRAMME
13.00-14.00 - ROOM 4
13.28 BOTH MEDICAL AND SURGICAL TREATMENT FOR
UNILATERAL PRIMARY ALDOSTERONISM LEAD TO BLOOD Workshop
PRESSURE IMPROVEMENTS
T. Puar, P. Kek, L. Ming, W. Loh, D. Lim, P. Tin, M. Zhang, L. Lee,
TREATING HYPERTENSIVE PATIENTS WITH
D. Swee, D. Tay, S. Tan, J. Khoo, R. Foo
Singapore, SINGAPORE DIFFERENT NEUROLOGIC CONDITIONS AND AGE
GROUPS: TARGETS
13.35 HIGH LEVEL OF PLASMA ALDOSTERONE AFTER SALINE Chairpersons: P. Cunha (Guimarães, PORTUGAL),
INFUSION TEST IN COMBINATION WITH FINDING OF ADRENAL D. Hering (Gdansk, AUSTRALIA)
NODE ON CT SCAN CAN PREDICT ALDOSTERONE-PRODUCING
ADENOMA MORE PRECISE THAN FINDING OF NODE ALONE
R. Holaj, J. Kvasnicka, J. Rosa, T. Zelinka, O. Petrak, B. Strauch, 13.00-13.20 The neurovascular and neurodegenerative conditions
Z. Kratka, T. Indra, L. Forejtova, J. Kavan, P. Waldauf, J. Widimsky D. Gasecki (Gdansk, POLAND)
Prague, CZECH REPUBLIC
13.20-13.40 Treatment strategies and BP targets to prevent
13.42 IIMAGING OF PRIMARY ALDOSTERONISM IN YOUNG cognitive decline in hypertension
PATIENTS FROM A LARGE INTERNATIONAL STUDY (AVIS-2- A. Coca (Barcelona, SPAIN)
YOUNG)
G.P. Rossi, F. Crimì 13.40-14.00 Discussion
Padua, ITALY
88
WEDNESDAY, APRIL 14 SCIENTIFIC PROGRAMME
14.00-15.00 - AUDITORIUM
14.00-14.15 Pro
M. Stowasser (Brisbane-QLD, AUSTRALIA)
14.15-14.30 Against
M. Brown (Cambridge, UNITED KINGDOM)
14.30-14.40 Discussion
89
ORGANISING AND SCIENTIFIC SECRETARIAT